Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG).
Yeo W, Boyer M, Chung HC, Ong SY, Lim R, Zee B, Ma B, Lam KC, Mo FK, Ng EK, Ho R, Clarke S, Roh JK, Beale P, Rha SY, Jeung HC, Soo R, Goh BC, Chan AT; Cancer Therapeutics Research Group (CTRG).
Yeo W, et al. Among authors: chan at.
Cancer Chemother Pharmacol. 2007 Feb;59(3):295-300. doi: 10.1007/s00280-006-0270-1. Epub 2006 Jun 17.
Cancer Chemother Pharmacol. 2007.
PMID: 16783579
Clinical Trial.